Personalized Treatment Plans
497 articles
Two-Drug Combo Targets KRAS and Fights Resistance
Researcher Hervé Tiriac leads a clinical trial for a new drug combination targeting KRAS and chemotherapy resistance.
The American Association for Cancer Research (AACR) Virtual Special Conference: Pancreatic Cancer Day One
Let’s Win and the Lustgarten Foundation present highlights of Day One of the AACR Virtual Special Conference on Pancreatic Cancer.
Researching More Second-Line Options for Pancreatic Cancer
Dr. Allyson Ocean explains the concept behind a novel second-line treatment being tested for metastatic pancreatic cancer.
New Data Support Preoperative Chemoradiation Regimen for Borderline Resectable Pancreatic Cancer
Should patients get chemotherapy or chemoradiation before surgery? Dr. Matthew Katz provides an update on the Alliance study.
A Look at MEK and Autophagy Inhibition
Dr. Conan Kinsey looks at the MEK pathway as way to make immunotherapy more effective for pancreatic cancer patients.
Living With
A New Chemotherapy and Radiation Regimen to Shrink Tumors Before Surgery
Researchers are testing a new combination of chemotherapies and radiation to shrink pancreatic cancer tumors and make surgical removal possible.
Nutrition Myths Debunked
Does sugar really feed cancer? Is a keto diet better for cancer? Should cancer patients avoid fats? Dietitians L.J. Amaral and Jessica Harrison take on common nutrition myths.
DIRECT Study Focuses on NanoKnife Technology
Dr. Daniel Holzwanger is part of the NanoKnife irreversible electroporation (IRE) study for stage III pancreatic cancer patients.
CAR T Cell Trial Targets Mesothelin
In an immunotherapy clinical trial, Dr. Mark O’Hara is using CAR T cells to attack mesothelin-expressing tumor cells in pancreatic cancer.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
Making Surgery An Option for More Pancreatic Cancer Patients
Dr. John Chabot explains that more pancreatic cancer patients may qualify for surgery if they consult an experience pancreatic surgical team.
Targeting Tumor Proteins Specific to Pancreatic Cancer Cells
A clinical trial tests the safety and effectiveness of tumor-associated antigen-specific cytotoxic T lymphocytes, which target specific tumor proteins.
Targeted Therapy for Pancreatic Cancer
Dr. Margaret Tempero outlines the work being done in the area of targeted therapy for pancreatic cancer, specifically the testing of ibrutinib.